NURECA

Nureca Limited

Nureca Limited (NURECA) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Healthcare Equipment & Supplies›Medical Equipment & Supplies

nureca.com

Ask AI

Key metrics

Price as of 2026-10-19

Stock price

₹313.25

Market cap

299 Cr

Stock P/E

69.0

P/B

1.65

Dividend yield

1.7%

ROE (FY26)

1.2%

ROCE (FY26)

3.5%

Operating margin (FY26)

-1.2%

Debt / equity (FY26)

0.0040

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Nureca (Dr Trust) designs and sells branded home healthcare and wellness devices, such as blood pressure monitors, nebulizers, thermometers and massagers, mostly through online channels in India.

Company snapshot

8thBy market cap

Ranked among 8 companies in Medical Equipment & Supplies.

What we see

Positives

✓Cash flow from operations is higher than reported profit — earnings quality looks solid.

Concerns

✗Net margin is very thin at 1.4% — little room for error if costs rise.

2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

Metric	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026	Jun 2026
Sales	31 Cr	22 Cr	17 Cr	20 Cr	31 Cr	26 Cr	32 Cr	34 Cr	38 Cr	40 Cr	35 Cr	40 Cr
Operating expenses (approx.)	30 Cr	27 Cr	21 Cr	23 Cr	34 Cr	30 Cr	31 Cr	35 Cr	34 Cr	36 Cr	41 Cr	37 Cr
EBITDA	1 Cr	-4 Cr	-4 Cr	-2 Cr	-2 Cr	-4 Cr	1 Cr	-0.56 Cr	3 Cr	3 Cr	-6 Cr	3 Cr
OPM %	4.4%	-19.0%	-26.1%	-11.7%	-7.6%	-15.2%	3.8%	-1.6%	8.7%	8.2%	-16.3%	8.5%
Other income	3 Cr	6 Cr	-1 Cr	6 Cr	3 Cr	1 Cr	2 Cr	3 Cr	2 Cr	2 Cr	1 Cr	2 Cr
Interest	0.08 Cr	0.11 Cr	0.18 Cr	0.15 Cr	0.27 Cr	0.17 Cr	0.62 Cr	0.25 Cr	0.46 Cr	0.28 Cr	0.30 Cr	0.20 Cr
Depreciation	0.59 Cr	0.59 Cr	0.60 Cr	0.66 Cr	0.62 Cr	0.54 Cr	0.52 Cr	0.53 Cr	0.54 Cr	0.50 Cr	0.45 Cr	0.61 Cr
Profit before tax	4 Cr	0.94 Cr	-6 Cr	3 Cr	-0.07 Cr	-3 Cr	2 Cr	1 Cr	5 Cr	5 Cr	-6 Cr	4 Cr
Tax %	26.0%	82.5%	35.9%	36.5%	-542.7%	13.9%	-20.3%	34.0%	21.1%	19.9%	-10.5%	30.8%
Net profit	3 Cr	0.17 Cr	-4 Cr	2 Cr	-0.48 Cr	-3 Cr	2 Cr	0.81 Cr	4 Cr	4 Cr	-6 Cr	3 Cr
EPS (₹)	₹2.90	₹0.16	₹-4.15	₹1.66	₹-0.48	₹-2.80	₹2.47	₹0.81	₹3.63	₹3.91	₹-6.45	₹3.21

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

Metric	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	99 Cr	213 Cr	256 Cr	111 Cr	92 Cr	110 Cr	147 Cr	Sign in free for the trailing twelve months
Operating expenses (approx.)	90 Cr	152 Cr	200 Cr	126 Cr	102 Cr	117 Cr	147 Cr	Sign in free for the trailing twelve months
EBITDA	10 Cr	62 Cr	56 Cr	-15 Cr	-10 Cr	-8 Cr	0.18 Cr	Sign in free for the trailing twelve months
OPM %	9.8%	28.8%	21.7%	-13.5%	-11.1%	-6.9%	0.1%	Sign in free for the trailing twelve months
Other income	0.06 Cr	3 Cr	8 Cr	7 Cr	11 Cr	12 Cr	8 Cr	Sign in free for the trailing twelve months
Interest	0.77 Cr	2 Cr	0.74 Cr	0.45 Cr	0.49 Cr	1 Cr	1 Cr	Sign in free for the trailing twelve months
Depreciation	0.37 Cr	0.42 Cr	1 Cr	2 Cr	2 Cr	2 Cr	2 Cr	Sign in free for the trailing twelve months
Profit before tax	9 Cr	62 Cr	61 Cr	-11 Cr	-3 Cr	1 Cr	5 Cr	Sign in free for the trailing twelve months
Tax %	25.7%	25.6%	26.3%	23.2%	29.5%	37.0%	58.2%	Sign in free for the trailing twelve months
Net profit	6 Cr	46 Cr	45 Cr	-8 Cr	-2 Cr	0.85 Cr	2 Cr	Sign in free for the trailing twelve months
EPS (₹)	₹9.14	₹62.04	₹44.96	₹-8.25	₹-1.79	₹0.85	₹2.11	Sign in free for the trailing twelve months
Dividend payout %	—	0.0%	11.1%	—	—	0.0%	0.0%	Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

Metric	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	0.01 Cr	10 Cr	10 Cr	10 Cr	10 Cr	10 Cr	10 Cr
Reserves	15 Cr	153 Cr	193 Cr	185 Cr	183 Cr	184 Cr	171 Cr
Borrowings	9 Cr	4 Cr	4 Cr	3 Cr	0.48 Cr	2 Cr	0.72 Cr
Other liabilities	10 Cr	19 Cr	12 Cr	8 Cr	12 Cr	13 Cr	15 Cr
Total liabilities	34 Cr	186 Cr	219 Cr	207 Cr	205 Cr	210 Cr	196 Cr
Fixed assets (net)	0.46 Cr	0.75 Cr	4 Cr	3 Cr	3 Cr	5 Cr	11 Cr
CWIP	—	0 Cr	0 Cr	0 Cr	0.27 Cr	0 Cr	0 Cr
Investments	—	0 Cr	33 Cr	59 Cr	94 Cr	1 Cr	1 Cr
Loans & advances	—	0.52 Cr	0 Cr	0 Cr	0 Cr	0 Cr	0 Cr
Inventories	16 Cr	37 Cr	63 Cr	34 Cr	31 Cr	40 Cr	48 Cr
Trade receivables	13 Cr	4 Cr	3 Cr	4 Cr	2 Cr	3 Cr	8 Cr
Cash & bank	0.07 Cr	17 Cr	8 Cr	0.50 Cr	14 Cr	3 Cr	1 Cr
Other assets	4 Cr	127 Cr	108 Cr	105 Cr	62 Cr	158 Cr	128 Cr
Total assets	34 Cr	186 Cr	219 Cr	207 Cr	205 Cr	210 Cr	196 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

Metric	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	-8 Cr	35 Cr	1 Cr	10 Cr	-3 Cr	-19 Cr	3 Cr
Cash from investing	-0.39 Cr	-110 Cr	-3 Cr	-16 Cr	18 Cr	8 Cr	14 Cr
Cash from financing	8 Cr	92 Cr	-7 Cr	-2 Cr	-1 Cr	-0.17 Cr	-20 Cr
Net cash flow	-0.04 Cr	17 Cr	-9 Cr	-8 Cr	14 Cr	-11 Cr	-2 Cr
Free cash flow (OCF − Capex)	-8 Cr	-75 Cr	-5 Cr	10 Cr	-4 Cr	-23 Cr	-4 Cr

Ratios

Metric	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROCE %	38.5%	38.4%	29.7%	-5.2%	-1.1%	1.3%	3.5%
ROE %	42.8%	28.4%	22.1%	-4.2%	-0.9%	0.4%	1.2%
Debtor days	47	6	4	14	6	11	19
Inventory days	60	63	90	3567	1154	1287	610
Days payable	21	15	7	516	193	211	65
Cash conversion cycle	86	54	87	3065	967	1086	564
OCF / EBITDA %	-81.7%	56.7%	2.5%	—	—	—	n.m.
OCF / EBITDA % (3 years)	—	—	22.4%	45.6%	29.4%	—	—
Debt / equity	0.63	0.02	0.02	0.02	0.0025	0.01	0.0040
Current ratio	3.45	9.60	16.85	21.00	20.77	15.32	8.32
Net debt / EBITDA	0.96	-0.22	-0.07	—	—	—	-4.09